{"title":"新的每日持续性头痛","authors":"K. Peng, M. Robbins, Shuu-Jiun Wang","doi":"10.1093/med/9780198724322.003.0030","DOIUrl":null,"url":null,"abstract":"New daily persistent headache (NDPH) is a rare headache syndrome affecting both paediatric and adult populations. In the latest revision of International Classification of Headache Disorders, 3rd edition (ICHD-3 beta), it is defined by the onset of daily and unremitting headaches within 24 hours lasting for more than 3 months. Common triggers include flu-like symptoms and stressful life events; however, the pathophysiology is largely unknown. Regarding headache features, in the ICHD-3 beta, migrainous features are allowed in comparison with ICHD-2. Different triggers and heterogeneous clinical presentations suggest that NDPH is more likely a syndrome, rather than a disease entity. Secondary aetiologies must be carefully excluded, especially meningitis, high and low intracranial pressure headaches, medication overuse headache, or reversible cerebral vasoconstriction syndrome. There are no randomized placebo-controlled trials for NDPH; thus, the treatment is mostly empirical. Most patients have persistent headache despite treatment, but approximately one-quarter of them reached remission, usually within 24 months. However, a subgroup of those who reached remission initially might experience relapse after months or years free from pain.","PeriodicalId":281151,"journal":{"name":"Oxford Textbook of Headache Syndromes","volume":"31 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New daily persistent headache\",\"authors\":\"K. Peng, M. Robbins, Shuu-Jiun Wang\",\"doi\":\"10.1093/med/9780198724322.003.0030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New daily persistent headache (NDPH) is a rare headache syndrome affecting both paediatric and adult populations. In the latest revision of International Classification of Headache Disorders, 3rd edition (ICHD-3 beta), it is defined by the onset of daily and unremitting headaches within 24 hours lasting for more than 3 months. Common triggers include flu-like symptoms and stressful life events; however, the pathophysiology is largely unknown. Regarding headache features, in the ICHD-3 beta, migrainous features are allowed in comparison with ICHD-2. Different triggers and heterogeneous clinical presentations suggest that NDPH is more likely a syndrome, rather than a disease entity. Secondary aetiologies must be carefully excluded, especially meningitis, high and low intracranial pressure headaches, medication overuse headache, or reversible cerebral vasoconstriction syndrome. There are no randomized placebo-controlled trials for NDPH; thus, the treatment is mostly empirical. Most patients have persistent headache despite treatment, but approximately one-quarter of them reached remission, usually within 24 months. However, a subgroup of those who reached remission initially might experience relapse after months or years free from pain.\",\"PeriodicalId\":281151,\"journal\":{\"name\":\"Oxford Textbook of Headache Syndromes\",\"volume\":\"31 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oxford Textbook of Headache Syndromes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/med/9780198724322.003.0030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford Textbook of Headache Syndromes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/med/9780198724322.003.0030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New daily persistent headache (NDPH) is a rare headache syndrome affecting both paediatric and adult populations. In the latest revision of International Classification of Headache Disorders, 3rd edition (ICHD-3 beta), it is defined by the onset of daily and unremitting headaches within 24 hours lasting for more than 3 months. Common triggers include flu-like symptoms and stressful life events; however, the pathophysiology is largely unknown. Regarding headache features, in the ICHD-3 beta, migrainous features are allowed in comparison with ICHD-2. Different triggers and heterogeneous clinical presentations suggest that NDPH is more likely a syndrome, rather than a disease entity. Secondary aetiologies must be carefully excluded, especially meningitis, high and low intracranial pressure headaches, medication overuse headache, or reversible cerebral vasoconstriction syndrome. There are no randomized placebo-controlled trials for NDPH; thus, the treatment is mostly empirical. Most patients have persistent headache despite treatment, but approximately one-quarter of them reached remission, usually within 24 months. However, a subgroup of those who reached remission initially might experience relapse after months or years free from pain.